Michael Aguiar - Theravance Insider

THRX -- USA Stock  

null 9.81  9.81  9,223,372,036,855%

CEO and President and Director

Mr. Michael W. Aguiar serves as President Chief Executive Officer Director of Theravance Inc. effective August 15 2014. He was appointed President and Chief Executive Officer of Innoviva Inc. and became a member of our Board of Directors in August 2014. He joined Innoviva as Senior Vice President and Chief Financial Officer in March 2005. Prior to joining Innoviva Mr. Aguiar served as Vice President of Finance at Gilead Sciences Inc. a biopharmaceutical company since 2002. Prior to Gilead Sciences Inc. Mr. Aguiar served as Vice President of Finance at Immunex Corporationrationration a biopharmaceutical company from 2001 to 2002. From 1995 to 2001 he was with Honeywell International in a variety of positions including most recently CFO and Vice President Finance for Honeywell Electronic Materials SBU. Mr. Aguiar earned a B.S. in biology from the University of California Irvine and an M.B.A. in finance from the University of Michigan. Mr. Aguiar demonstrated leadership in his field his prior senior management experience in our industry and his experience as our Chief Executive Officer and as our former Chief Financial Officer contributed to our conclusion that he should serve as a director.
Age: 48  CEO Since 2014  MBA    
650-238-9600  http://www.thrxinc.com
Aguiar earned a B.S. in Biology from UC Irvine and an M.B.A. in Finance from the University of Michigan.

Michael Aguiar Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 1.82 % which means that it generated profit of $1.82 on every $100 spent on asset. This is way below average.
The company currently holds 744.09 M in liabilities with Debt to Equity (D/E) ratio of 1.09 which is about average as compared to similar companies. Theravance has Current Ratio of 19.44 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Theravance, Inc., a royalty management company, is focused on developing respiratory products. Theravance (THRX) is traded on NASDAQ in USA. It is located in South San Francisco, CA and employs 13 people.

Theravance Leadership Team

Catherine Friedman, Director
Michael Aguiar, CEO, MBA
Barbara Duncan, Director
Paul Pepe, Director
George Abercrombie, President, MBA
Patrick LePore, Director
James Tyree, Director
Eric dEsparbes, CFO
Terrence Kearney, Director
Michael Faerm, SVP, MBA
Theodore Witek, SVP, MBA
William Waltrip, Director

Stock Performance Indicators

Did you try this?

Run Equity Analysis Now
   

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
All  Next Launch Equity Analysis

Trending Equities

Currently Active Assets on Macroaxis
OZL   
Purchased over 100 shares of
few days ago
Traded for 10.44
FBU   
Purchased over 300 shares of
few days ago
Traded for 6.24
JBH   
Purchased over 70 shares of
few days ago
Traded for 23.42
GNC   
Purchased over 200 shares of
few days ago
Traded for 8.1
SBM   
Purchased over 400 shares of
few days ago
Traded for 4.74
Also please take a look at World Market Map. Please also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. drill down to check world indexes.